| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA565: Benralizumab for treating severe eosinophilic asthma |
|
Medicine details |
|
| Medicine name | benralizumab (Fasenra®) |
| Formulation | 30 mg subcutaneous injection |
| Reference number | 2452 |
| Indication | As an add‑on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long‑acting β‑agonist |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/11/2017 |
| NICE guidance | |